RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$14.89
0.00%
(0.00) 1D
Okt 7, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa RARE...
Mkt. cap
1.47B
Avg. na dami
5.89M
Dami
1.46K
Mataas nang 52-wk
$39.89
Mababa nang 52-wk
$12.73
EPS
-$5.84
Beta
0.35
Mga natitirang share
98.59M
Bilang ng mga empleyado
1K
Mkt. cap
1.47B
Avg. na dami
5.89M
Dami
1.46K
Mataas nang 52-wk
$39.89
Mababa nang 52-wk
$12.73
EPS
-$5.84
Beta
0.35
Mga natitirang share
98.59M
Bilang ng mga empleyado
1K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Investing.com
·
1 oras ang nakalipas
H.C. Wainwright reiterates Ultragenyx stock rating on PRV sale
Investing.com Nigeria
·
10 oras ang nakalipas
Form PRE 14A Ultragenyx Pharmaceutical Inc For: 7 October By Investing.com
Pluang
·
20 oras ang nakalipas
Ultragenyx shares rise 3.2% after selling FDA p...
MarketBeat
·
20 oras ang nakalipas
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9% - Here's Why
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Tungkol sa Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Mga Empleyado1.37K
Itinatag2010
HeadquartersNovato, California, Estados Unidos
Sektor-
Websiteultragenyx.com